1. A therapy for suppressing canonical and noncanonical SARS-CoV-2 viral entry and an intrinsic intrapulmonary inflammatory response
- Author
-
Leibel, Sandra L, McVicar, Rachael N, Murad, Rabi, Kwong, Elizabeth M, Clark, Alex E, Alvarado, Asuka, Grimmig, Bethany A, Nuryyev, Ruslan, Young, Randee E, Lee, Jamie C, Peng, Weiqi, Zhu, Yanfang P, Griffis, Eric, Nowell, Cameron J, James, Brian, Alarcon, Suzie, Malhotra, Atul, Gearing, Linden J, Hertzog, Paul J, Galapate, Cheska M, Galenkamp, Koen MO, Commisso, Cosimo, Smith, Davey M, Sun, Xin, Carlin, Aaron F, Sidman, Richard L, Croker, Ben A, and Snyder, Evan Y
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Biological Sciences ,Stem Cell Research - Induced Pluripotent Stem Cell - Human ,Coronaviruses ,Emerging Infectious Diseases ,Stem Cell Research ,Infectious Diseases ,Lung ,Stem Cell Research - Induced Pluripotent Stem Cell ,2.1 Biological and endogenous factors ,Inflammatory and immune system ,Infection ,Humans ,SARS-CoV-2 ,COVID-19 ,Virus Internalization ,Organoids ,COVID-19 Drug Treatment ,Induced Pluripotent Stem Cells ,Angiotensin-Converting Enzyme 2 ,Inflammation ,Cytokines ,Apoptosis ,inflammation ,lung organoids ,macropinocytosis ,surfactant - Abstract
The prevalence of "long COVID" is just one of the conundrums highlighting how little we know about the lung's response to viral infection, particularly to syndromecoronavirus-2 (SARS-CoV-2), for which the lung is the point of entry. We used an in vitro human lung system to enable a prospective, unbiased, sequential single-cell level analysis of pulmonary cell responses to infection by multiple SARS-CoV-2 strains. Starting with human induced pluripotent stem cells and emulating lung organogenesis, we generated and infected three-dimensional, multi-cell-type-containing lung organoids (LOs) and gained several unexpected insights. First, SARS-CoV-2 tropism is much broader than previously believed: Many lung cell types are infectable, if not through a canonical receptor-mediated route (e.g., via Angiotensin-converting encyme 2(ACE2)) then via a noncanonical "backdoor" route (via macropinocytosis, a form of endocytosis). Food and Drug Administration (FDA)-approved endocytosis blockers can abrogate such entry, suggesting adjunctive therapies. Regardless of the route of entry, the virus triggers a lung-autonomous, pulmonary epithelial cell-intrinsic, innate immune response involving interferons and cytokine/chemokine production in the absence of hematopoietic derivatives. The virus can spread rapidly throughout human LOs resulting in mitochondrial apoptosis mediated by the prosurvival protein Bcl-xL. This host cytopathic response to the virus may help explain persistent inflammatory signatures in a dysfunctional pulmonary environment of long COVID. The host response to the virus is, in significant part, dependent on pulmonary Surfactant Protein-B, which plays an unanticipated role in signal transduction, viral resistance, dampening of systemic inflammatory cytokine production, and minimizing apoptosis. Exogenous surfactant, in fact, can be broadly therapeutic.
- Published
- 2024